Browsing by Author "Quera, Rodrigo"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Increased production of soluble TLR2 by lamina propria mononuclear cells from ulcerative colitis patients
    (ELSEVIER GMBH, 2012) Candia, Enzo; Diaz Jimenez, David; Langjahr, Patricia; Nunez, Lucia E.; de la Fuente, Marjorie; Farfan, Nancy; Lopez Kostner, Francisco; Abedrapo, Mario; Alvarez Lobos, Manuel; Pinedo, George; Beltran, Caroll J.; Gonzalez, Carlos; Gonzalez, Maria Julieta; Quera, Rodrigo; Hermoso, Marcela A.
    Toll-like receptor 2 (TLR2) is a type I pattern recognition receptor that has been shown to participate in intestinal homeostasis. Its increased expression in the lamina propria has been associated with the pathogenesis in inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Recently, soluble TLR2 (sTLR2) variants have been shown to counteract inflammatory responses driven by the cognate receptor. Despite the evident roles of TLR2 in intestinal immunity, no study has elucidated the production and cellular source of sTLR2 in IBD. Furthermore, an increase in the population of activated macrophages expressing TLR2 that infiltrates the intestine in IBD has been reported. We aimed first to assess the production of the sTLR2 by UC and CD organ culture biopsies and lamina propria mononuclear cells (LPMCs) as well as the levels of sTLR2 in serum, and then characterize the cell population from lamina propria producing the soluble protein.
  • No Thumbnail Available
    Item
    Rectal diffuse large B cell lymphoma appearing after immunosuppression for ulcerative colitis. Report of one case
    (SOC MEDICA SANTIAGO, 2017) Quera, Rodrigo; Flores, Lilian; Simian, Daniela; Kronberg, Udo; Teresa Vial, Maria; Ladron De Guevara, David; Jose Garcia Rodriguez, Maria
    Primary colorectal lymphoma is a rare form of presentation of gastrointestinal tract lymphomas. Inflammatory bowel disease and its treatment are risk factors for its development. We report a 47-year-old male patient with Ulcerative Colitis of two years of evolution, treated initially with azathioprine and later on with infliximab. Due to a relapse in symptoms after the second dose of infliximab, a new coloncoscopy was performed showing a rectal ulcerative lesion, corresponding to a large cell Non-Hodgkin's Lymphoma. The patient was successfully treated with RCHOP chemotherapy (Rituximab cyclophosphamide doxorubicin vincristine prednisone). He is currently in disease remission.
  • Thumbnail Image
    Item
    Soluble ST2: A new and promising activity marker in ulcerative colitis
    (BAISHIDENG PUBL GRP CO LTD, 2011) Diaz Jimenez, David; Nunez, Lucia E.; Beltran, Caroll J.; Candia, Enzo; Suazo, Cristobal; Alvarez Lobos, Manuel; Gonzalez, Maria Julieta; Hermoso, Marcela A.; Quera, Rodrigo
    AIM: To correlate circulating soluble ST2 (sST2) levels with the severity of ulcerative colitis (UC) and serum levels of pro-inflammatory cytokines, and to demonstrate the predictive power of sST2 levels for differentiation between active and inactive UC.